drugset / Trial / NCT00351637

Sublingual Methadone for the Management of Cancer-related Procedure Pain in Inpatients

NCT00351637

Phase 2 Terminated 60 enrolled Alberta Health services
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this Phase II study is to determine the feasibility of the dose titration and assessment protocol in the impatient population, in the clinical setting of preventing or managing breakthrough pain, before conducting an appropriately powered phase III study. Thus the primary purpose of this study is to determine the proportion of patients who are successfully titrated to an effective dose of sublingual methadone.

Timeline

Start
2006-12
Primary completion
2008-09
Completion
2008-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Methadone Other / unclassified Other

Indications